Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Wijnhoven PWG"'
Autor:
Adriaens C; Laboratory for Molecular Cancer Biology, Center for the Biology of Disease, VIB, KU Leuven, Leuven, Belgium.; Laboratory for Molecular Cancer Biology, Center for Human Genetics, KU Leuven, Leuven, Belgium., Standaert L; Laboratory for Molecular Cancer Biology, Center for the Biology of Disease, VIB, KU Leuven, Leuven, Belgium.; Laboratory for Molecular Cancer Biology, Center for Human Genetics, KU Leuven, Leuven, Belgium., Barra J; Laboratory for Molecular Cancer Biology, Center for the Biology of Disease, VIB, KU Leuven, Leuven, Belgium.; Laboratory for Molecular Cancer Biology, Center for Human Genetics, KU Leuven, Leuven, Belgium., Latil M; Université Libre de Bruxelles, Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Bruxelles, Belgium., Verfaillie A; Laboratory of Computational Biology, Center for Human Genetics, KU Leuven, Leuven, Belgium., Kalev P; Laboratory for Mechanisms of Cell Transformation, Center for the Biology of Disease, VIB, KU Leuven, Leuven, Belgium.; Laboratory for Mechanisms of Cell Transformation, Center for Human Genetics, KU Leuven, Leuven, Belgium., Boeckx B; Vesalius Research Center, VIB, KU Leuven, Leuven, Belgium.; Department of Oncology, Laboratory for Translational Genetics, KU Leuven, Leuven, Belgium., Wijnhoven PWG; The Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge, UK., Radaelli E; Mouse Histopathology Core Facility, Center for the Biology of Disease, VIB, KU Leuven, Leuven, Belgium., Vermi W; Department of Molecular and Translational Medicine, Section of Pathology, University of Brescia, Brescia, Italy.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA., Leucci E; Laboratory for Molecular Cancer Biology, Center for the Biology of Disease, VIB, KU Leuven, Leuven, Belgium.; Laboratory for Molecular Cancer Biology, Center for Human Genetics, KU Leuven, Leuven, Belgium., Lapouge G; Université Libre de Bruxelles, Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Bruxelles, Belgium., Beck B; Université Libre de Bruxelles, Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Bruxelles, Belgium., van den Oord J; Department of Pathology, Laboratory of Translational Cell and Tissue Research, KU Leuven and UZ Leuven, Leuven, Belgium., Nakagawa S; RNA Biology Laboratory, RIKEN, Wako, Japan.; Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan., Hirose T; Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan., Sablina AA; Laboratory for Mechanisms of Cell Transformation, Center for the Biology of Disease, VIB, KU Leuven, Leuven, Belgium.; Laboratory for Mechanisms of Cell Transformation, Center for Human Genetics, KU Leuven, Leuven, Belgium., Lambrechts D; Vesalius Research Center, VIB, KU Leuven, Leuven, Belgium.; Department of Oncology, Laboratory for Translational Genetics, KU Leuven, Leuven, Belgium., Aerts S; Laboratory of Computational Biology, Center for Human Genetics, KU Leuven, Leuven, Belgium., Blanpain C; Université Libre de Bruxelles, Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Bruxelles, Belgium.; WELBIO, Université Libre de Bruxelles, Bruxelles, Belgium., Marine JC; Laboratory for Molecular Cancer Biology, Center for the Biology of Disease, VIB, KU Leuven, Leuven, Belgium. jeanchristophe.marine@cme.vib-kuleuven.be.; Laboratory for Molecular Cancer Biology, Center for Human Genetics, KU Leuven, Leuven, Belgium. jeanchristophe.marine@cme.vib-kuleuven.be.
Publikováno v:
Nature medicine [Nat Med] 2024 May; Vol. 30 (5), pp. 1506.
Autor:
Sharma AB; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK., Ramlee MK; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK., Kosmin J; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK., Higgs MR; Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, UK., Wolstenholme A; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK., Ronson GE; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK.; Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, UK., Jones D; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Ebner D; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Shamkhi N; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK., Sims D; Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK., Wijnhoven PWG; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK., Forment JV; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK., Gibbs-Seymour I; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK., Lakin ND; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK. nicholas.lakin@bioch.ox.ac.uk.
Publikováno v:
Nature communications [Nat Commun] 2023 Nov 27; Vol. 14 (1), pp. 7784. Date of Electronic Publication: 2023 Nov 27.
Autor:
Sharma AB; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK., Ramlee MK; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK., Kosmin J; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK., Higgs MR; Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, UK., Wolstenholme A; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK., Ronson GE; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK.; Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, UK., Jones D; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Ebner D; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Shamkhi N; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK., Sims D; Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK., Wijnhoven PWG; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK., Forment JV; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK., Gibbs-Seymour I; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK., Lakin ND; Department of Biochemistry, University of Oxford, South Parks Road, Oxford, UK. nicholas.lakin@bioch.ox.ac.uk.
Publikováno v:
Nature communications [Nat Commun] 2023 Aug 17; Vol. 14 (1), pp. 5003. Date of Electronic Publication: 2023 Aug 17.
Autor:
Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Wang AT; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Castroviejo-Bermejo M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Polanska UM; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Palafox M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Herencia-Ropero A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain., Jones GN; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Lai Z; AstraZeneca Oncology R&D, Waltham, Massachusetts., Armenia J; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Michopoulos F; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Llop-Guevara A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Brough R; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Gulati A; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Pettitt SJ; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Bulusu KC; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Nikkilä J; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Wilson Z; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Hughes A; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Wijnhoven PWG; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Ahmed A; AstraZeneca Oncology R&D, Waltham, Massachusetts., Bruna A; Cancer Research UK, Cambridge Institute, Cambridge, United Kingdom., Gris-Oliver A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Guzman M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Rodríguez O; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Grueso J; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Arribas J; CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Cortés J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Saura C; Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Lau A; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Critchlow S; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Dougherty B; AstraZeneca Oncology R&D, Waltham, Massachusetts., Caldas C; Cancer Research UK, Cambridge Institute, Cambridge, United Kingdom., Mills GB; Department of Cell Development and Cancer Biology, Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon.; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Barrett JC; AstraZeneca Oncology R&D, Waltham, Massachusetts., Forment JV; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Cadogan E; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Lord CJ; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom., Cruz C; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.; High Risk and Familial Cancer, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Balmaña J; Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.; High Risk and Familial Cancer, Vall d'Hebron Institute of Oncology, Barcelona, Spain., O'Connor MJ; AstraZeneca Oncology R&D, Cambridge, United Kingdom.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Oct 14; Vol. 28 (20), pp. 4536-4550.
Autor:
Wilson Z; Bioscience, Oncology R&D, AstraZeneca, Cheshire, United Kingdom., Odedra R; Bioscience, Oncology R&D, AstraZeneca, Cheshire, United Kingdom., Wallez Y; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Wijnhoven PWG; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Hughes AM; Bioscience, Oncology R&D, AstraZeneca, Cheshire, United Kingdom., Gerrard J; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Jones GN; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Bargh-Dawson H; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Brown E; Bioscience, Oncology R&D, AstraZeneca, Cheshire, United Kingdom., Young LA; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., O'Connor MJ; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Lau A; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
Publikováno v:
Cancer research [Cancer Res] 2022 Mar 15; Vol. 82 (6), pp. 1140-1152.
Autor:
Gill SJ; Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Wijnhoven PWG; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Fok JHL; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Lloyd RL; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Cairns J; Discovery Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Armenia J; Bioinformatics and Data Science, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Nikkilä J; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Lau A; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Bakkenist CJ; Hillman Cancer Center 2.6, Pittsburgh, Pennsylvania., Galbraith SM; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Vens C; Department of Radiation Oncology, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands., O'Connor MJ; Oncology R&D, AstraZeneca, Cambridge, United Kingdom. mark.j.oconnor@astrazeneca.com.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Sep; Vol. 20 (9), pp. 1614-1626. Date of Electronic Publication: 2021 Jun 22.
Autor:
Lloyd RL; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.; The Wellcome trust and CRUK Gurdon Institute, and Department of Biochemistry, University of Cambridge, Cambridge, UK., Wijnhoven PWG; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Ramos-Montoya A; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Wilson Z; Bioscience, Oncology R&D, AstraZeneca, Alderley Park, UK., Illuzzi G; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Falenta K; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Jones GN; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK., James N; Bioscience, Oncology R&D, AstraZeneca, Alderley Park, UK., Chabbert CD; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Stott J; Quantitative Biology, Discovery Science, Oncology R&D, AstraZeneca, Cambridge, UK., Dean E; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Lau A; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Young LA; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK. Lucy.Young@astrazeneca.com.
Publikováno v:
Oncogene [Oncogene] 2020 Jun; Vol. 39 (25), pp. 4869-4883. Date of Electronic Publication: 2020 May 23.
Autor:
Fok JHL; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Ramos-Montoya A; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Vazquez-Chantada M; Mechanistic Biology and Profiling, Discovery Sciences, Oncology R&D, AstraZeneca, Cambridge, UK., Wijnhoven PWG; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Follia V; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., James N; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Farrington PM; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Karmokar A; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Willis SE; Translational Science, Oncology R&D, AstraZeneca, Cambridge, UK., Cairns J; Quantitative Biology, Discovery Science, Oncology R&D, AstraZeneca, Cambridge, UK., Nikkilä J; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Beattie D; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, UK., Lamont GM; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, UK., Finlay MRV; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, UK., Wilson J; DMPK, Oncology R&D, AstraZeneca, Cambridge, UK., Smith A; DMPK, Oncology R&D, AstraZeneca, Cambridge, UK., O'Connor LO; Translational Science, Oncology R&D, AstraZeneca, Cambridge, UK., Ling S; Mechanistic Biology and Profiling, Discovery Sciences, Oncology R&D, AstraZeneca, Cambridge, UK., Fawell SE; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., O'Connor MJ; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Hollingsworth SJ; Oncology Business Unit, AstraZeneca, Cambridge, UK., Dean E; Oncology Translational Medicine Unit, Early Clinical Development, Oncology R&D, AstraZeneca, Cambridge, UK., Goldberg FW; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, UK., Davies BR; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK., Cadogan EB; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK. elaine.cadogan@astrazeneca.com.
Publikováno v:
Nature communications [Nat Commun] 2019 Nov 07; Vol. 10 (1), pp. 5065. Date of Electronic Publication: 2019 Nov 07.
Autor:
Nishi R; The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QN, United Kingdom. rnishi@fc.ritsumei.ac.jp.; Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Shiga, 525-8577, Japan. rnishi@fc.ritsumei.ac.jp., Wijnhoven PWG; The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QN, United Kingdom.; Bioscience Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom., Kimura Y; Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Shiga, 525-8577, Japan., Matsui M; Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Shiga, 525-8577, Japan., Konietzny R; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7FZ, United Kingdom., Wu Q; Department of Biochemistry, University of Cambridge, Sanger Building, Tennis Court Road, Cambridge, CB2 1GA, United Kingdom., Nakamura K; Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Shiga, 525-8577, Japan., Blundell TL; Department of Biochemistry, University of Cambridge, Sanger Building, Tennis Court Road, Cambridge, CB2 1GA, United Kingdom., Kessler BM; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7FZ, United Kingdom.
Publikováno v:
Scientific reports [Sci Rep] 2018 Dec 17; Vol. 8 (1), pp. 17891. Date of Electronic Publication: 2018 Dec 17.